• Completed

NCT00048230: Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With RRMM

Updated: Apr 26

Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT00048230


velcade-dex

This study will compare the efficacy of PS-341 versus high dose dexamethasone.


Sponsor: Millennium Pharmaceuticals, Inc.


Multiple locations

International Study

 

ClinicalTrials.gov Identifier: NCT00048230


Official Title: An International, Multi-Center, Randomized, Open-Label Study of PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

https://clinicaltrials.gov/ct2/show/NCT00048230

 

Bortezomib : National Cancer Institute

Bortezomib : MedlinePlus Drug Information

 

Drug: Bortezomib


Bortezomib

bortezomib

BORTEZOMIB

LDP 341

MLN341

PS-341

PS341

velcade

Velcade

 

Retrospective matched-pairs analysis of bortezomib plus dexamethasone versus bortezomib monotherapy in relapsed multiple myeloma

Haematologica; 2015

https://pubmed.ncbi.nlm.nih.gov/25261096/



Sequence analysis of β-subunit genes of the 20S proteasome in patients with relapsed multiple myeloma treated with bortezomib or dexamethasone

Blood; 2012

https://pubmed.ncbi.nlm.nih.gov/23018640/



Impact of prior therapies on the relative efficacy of bortezomib compared with dexamethasone in patients with relapsed/refractory multiple myeloma

Br J Haematol; 2009

https://pubmed.ncbi.nlm.nih.gov/19725827/






Posts Archive